JPRN-UMIN000041621
Not yet recruiting
未知
Pooled safety and efficacy analysis of trifluridine/tipiracil plus bevacizumab in five clinical trials using individual data from patients with metastatic colorectal cancer - Pooled safety and efficacy analysis of trifluridine/tipiracil plus bevacizumab in five clinical trials using individual data from patients with metastatic colorectal cancer
The 22nd Century Cutting-Edge Medical Informaion Technology Organization0 sites239 target enrollmentSeptember 15, 2020
Conditionsmetastatic colorectal cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- metastatic colorectal cancer
- Sponsor
- The 22nd Century Cutting-Edge Medical Informaion Technology Organization
- Enrollment
- 239
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Nothing in particular
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Real-world Effectiveness and Safety of Trifluridine/Tipiracil plus bevacizumab in Metastatic Colorectal Cancer: A retrospective observational study using an administrative databaseColorectal cancerJPRN-jRCT1031220116Taiho Pharmaceutical Co., Ltd. Medical Affairs Division11,962
Completed
Phase 4
A clinical trial to study the effect of Triflusal in Aspirin resitant patientsCTRI/2011/04/001679Glenmark Pharmaceuticals Lts40
Active, not recruiting
Phase 1
Efficacy and safety of Trifluridine/Tipiracil in combination with Irinotecan as a secondline therapy in patients with bile duct cancerPatients with advanced, non resectable or metastatic cholangio- and gallbladder carcinoma after failure to respond to a previous gemcitabine treatment.Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-002936-26-DEHeinrich-Heine-University Düsseldorf28
Not yet recruiting
Not Applicable
A retrospective observational study of trifluridine tipiracil plus minus bevacizumab in pretreated mCRC patients with MSI-H MMR-D metastatic colorectal cancerJPRN-UMIN000051378The 22nd Century Cutting-Edge Medical Informaion Technology Organization15
Recruiting
Phase 2
Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5- fluorouracile ± nivolumab in frail patients with advanced, recurrent or metastatic gastric, oesophageal or gastroesophageal junction cancer2024-512999-35-00Unicancer118